Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cefepime + nacubactam or aztreonam + nacubactam versus imipenem + cilastatin in adult complicated urinary tract infection or acute pyelonephritis
CTR20233006Phase 3Completed
- Sponsor
- NA/ 上海复星医药产业发展有限公司
- Start
- Sep 2023
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nacubactam, cefepime, aztreonam, imipenem, cilastatin in complicated urinary tract infection (cUTI), acute pyelonephritis, Gram-negative bacterial infection, sponsored by NA/ 上海复星医药产业发展有限公司. Started Sep 2023; status: completed.
02
Drugs
Nacubactamcefepimeaztreonamimipenemcilastatin
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritisGram-negative bacterial infection
Beyond the preview
Go deeper on CTR20233006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233006.